129 related articles for article (PubMed ID: 30760500)
1. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
[TBL] [Abstract][Full Text] [Related]
2. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
[TBL] [Abstract][Full Text] [Related]
3. The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.
Cao M; Royce DB; Risingsong R; Williams CR; Sporn MB; Liby KT
Cancer Prev Res (Phila); 2016 Jan; 9(1):105-14. PubMed ID: 26554632
[TBL] [Abstract][Full Text] [Related]
4. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
5. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
[TBL] [Abstract][Full Text] [Related]
6. The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer.
Reich LA; Moerland JA; Leal AS; Zhang D; Carapellucci S; Lockwood B; Jurutka PW; Marshall PA; Wagner CE; Liby KT
Sci Rep; 2022 Jan; 12(1):293. PubMed ID: 34997154
[TBL] [Abstract][Full Text] [Related]
7. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
[TBL] [Abstract][Full Text] [Related]
8. A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.
Hanish BJ; Hackney Price JF; Kaneko I; Ma N; van der Vaart A; Wagner CE; Jurutka PW; Marshall PA
Steroids; 2018 Jul; 135():36-49. PubMed ID: 29704526
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
10. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract][Full Text] [Related]
11. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
12. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.
Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH
Br J Cancer; 2008 Apr; 98(8):1380-8. PubMed ID: 18362934
[TBL] [Abstract][Full Text] [Related]
13. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
Inoue M; Tanabe H; Nakashima K; Ishida Y; Kotani H
J Nat Prod; 2014 Jul; 77(7):1670-7. PubMed ID: 24959987
[TBL] [Abstract][Full Text] [Related]
14. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.
Liby K; Risingsong R; Royce DB; Williams CR; Ma T; Yore MM; Sporn MB
Cancer Prev Res (Phila); 2009 Dec; 2(12):1050-8. PubMed ID: 19952361
[TBL] [Abstract][Full Text] [Related]
15. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
16. Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism.
Uray IP; Rodenberg JM; Bissonnette RP; Brown PH; Mancini MA
Mol Pharmacol; 2012 Feb; 81(2):228-38. PubMed ID: 22053058
[TBL] [Abstract][Full Text] [Related]
17. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
18. Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.
Marshall PA; Jurutka PW; Wagner CE; van der Vaart A; Kaneko I; Chavez PI; Ma N; Bhogal JS; Shahani P; Swierski JC; MacNeill M
Pharmacol Res Perspect; 2015 Mar; 3(2):e00122. PubMed ID: 26038698
[TBL] [Abstract][Full Text] [Related]
19. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
[TBL] [Abstract][Full Text] [Related]
20. Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice.
Zhang Q; Pan J; Zhang J; Liu P; Chen R; Chen DR; Lubet R; Wang Y; You M
Cancer Prev Res (Phila); 2011 Feb; 4(2):270-6. PubMed ID: 21163938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
